Article

Foveal Intraretinal Fluid Localization Affects the Visual Prognosis of Branch Retinal Vein Occlusion

Hirofumi Sasajima 1,* , Masahiro Zako 2, Rio Maeda 1, Kenta Murotani 3, Hidetoshi Ishida 1,4 and Yoshiki Ueta 1,

1 Department of Ophthalmology, Shinseikai Toyama Hospital, Imizu 939-0243, Japan; r-maeda@shinseikai.or.jp (R.M.); ishi1214@kanazawa-med.ac.jp (H.I.); ueta@shinseikai.or.jp (Y.U.)
2 Department of Ophthalmology; Asai Hospital, Seto 489-0866, Japan; mzako@aol.com
3 Biostatistics Center, Kurume University, Kurume 830-0011, Japan; kmurotani@med.kurume-u.ac.jp
4 Department of Ophthalmology, Kanazawa Medical University, Kahoku 920-0293, Japan
* Correspondence: hiro.sasa1228@icloud.com; Tel.: +81-766-52-2156

Abstract: We investigated whether baseline foveal intraretinal fluid (IRF) localization affects the visual prognosis of branch retinal vein occlusion (BRVO). Fifty eyes from 50 patients were included in this retrospective study. We classified the eyes with IRF involving and not involving the central foveola on the vertical optical coherence tomography (OCT) image at the initial visit into both-sides (n = 17) and one-side IRF (n = 33) groups, respectively. Multiple regression analyses demonstrated that not only the baseline logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA) but also the IRF localization significantly correlated with the 12-month logMAR BCVA (p = 0.04 and p = 0.001, respectively), indicating that eyes with better baseline logMAR BCVA and one-side IRF have a significantly better visual prognosis in BRVO. The foveal ellipsoid zone band was significantly more disrupted (p < 0.001) in the both-sides IRF (47.1%) group than in the one-side IRF (3.0%) group. No eyes with decimal BCVA less than 0.5 were detected in the one-side IRF group at 12 months. Thus, baseline foveal IRF localization on vertical OCT images can be considered a novel biomarker for the visual prognosis of BRVO.

Keywords: branch retinal vein occlusion; visual prognostic factor; foveal intraretinal fluid; ellipsoid zone; macular edema; optical coherence tomography

1. Introduction

Elucidation of potential visual prognostic factors is important since it could contribute to patient counseling and treatment strategies. Several potential visual prognostic factors for branch retinal vein occlusion (BRVO) have been reported. Patient age [1–4] and baseline logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA) [1–3] are potential visual prognostic factors for BRVO.

High-resolution optical coherence tomography (OCT) has revealed several visual prognostic factors for BRVO, such as baseline central subfield thickness (CST) [3]. The correlation of CST with final visual acuity (VA) is somewhat controversial. Iida-Miwa et al. [3] reported that the baseline central foveal thickness is associated with the final VA. Meanwhile, other studies reported contradictory results [5–8].

OCT has helped identify other visual prognostic factors for BRVO, including integrity of the ellipsoid zone (EZ) [8,9] and external limiting membrane (ELM) [8,9] and disorganization of the retinal inner layers (DRIL) [10]. Sometimes, in acute-phase BRVO with severe retinal hemorrhage and macular edema (ME), evaluating the integrity of the EZ and ELM and the presence of DRIL on OCT images can be challenging. In comparison, determining whether intraretinal fluid (IRF) involves the central foveola through OCT can be easy in acute-phase BRVO.

We sometimes encounter eyes with IRF involving the central foveola, which have poor visual prognosis, in our clinical practice. These eyes with poor VA often show foveal EZ...
and EZ disruptions on OCT images after complete resolution of ME. Meanwhile, eyes with IRF not involving the central foveola usually do not display foveal ELM and EZ disruptions on OCT images after complete resolution of ME. Since IRF involving the central foveola could cause foveal photoreceptors damage, we hypothesized that IRF localization affects the visual prognosis of BRVO.

In the present study, we reviewed vertical OCT images of ME secondary to BRVO and investigated whether IRF involving the central foveola on vertical OCT images at the initial visit affects the visual prognosis of BRVO.

2. Materials and Methods
2.1. Patients

This retrospective observational study included patients with ME associated with treatment-naïve BRVO. The study protocol was approved by the Institutional Review Board of Shinseikai Toyama Hospital (reference number: 220422-1) and adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained from all the participants. We reviewed the medical and ocular histories of patients with ME attributed to BRVO treated with a single loading dose + pro re nata (one + PRN) regimen of intravitreal injections of aflibercept (Eylea®, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA) between 8 January 2018, and 4 April 2022, at the Department of Ophthalmology of the Shinseikai Toyama Hospital (Toyama, Japan).

The inclusion criteria were as follows: treatment-naïvety with ME within 6 months following BRVO onset and history of treatment with a one + PRN regimen of 2.0 mg/0.05 mL aflibercept over 12 months. Patients who had spectral-domain OCT images obtained at the initial visit were also included. The exclusion criteria were as follows: presence of central retinal vein occlusion, hemicentral retinal vein occlusion, significant media opacity and other retinal disorders, such as diabetic retinopathy. Patients who had undergone ocular surgery, such as cataract surgery or vitrectomy within 6 months and during the current study, undergone treatment including intravitreal injection of drugs, such as ranibizumab (Lucentis®, Genentech Inc., South San Francisco, CA, USA), aflibercept and triamcinolone acetonide (TA), or who were treated with a sub-Tenon injection of TA for at least 3 months following the treatment, were also excluded.

2.2. Examinations

During the study period, all the patients underwent comprehensive ophthalmic examinations, including BCVA measurement using a Landolt C-chart, slit-lamp biomicroscopy, indirect ophthalmoscopy, fundus camera (California, Optos PLC, Dunfermline, UK and/or TRC-NW8, Topcon, Tokyo, Japan), and OCT (Spectralis OCT, Heidelberg Engineering, Heidelberg, Germany and/or RS-3000, Nidek Co., Ltd., Gamagori, Japan). The area of retinal hemorrhage was manually measured by two observers (H.S. and R.M.) using the built-in software of the ultra-widefield fundus camera, and the area was automatically calculated in mm².

Fluorescein angiography was performed to evaluate the perfusion status in all patients using an ultra-widefield fundus camera. A nonperfusion area smaller than five disc diameters was considered perfused [11].

BRVO subtype (i.e., major or macular) was determined using a fundus camera based on the vein occlusion: major BRVO, occlusion of one of the four major branch retinal veins; and macular BRVO, occlusion of the veins in the macular region [12].

2.3. Definition and Classification of the Two Groups Using Optical Coherence Tomography

Based on the vertical OCT B-scan image through the fovea at the initial visit, we classified the eyes into two groups: the one-side IRF group included eyes with IRF not involving the central foveola (Figure 1), and the both-sides IRF group included eyes with IRF involving the central foveola (Figure 2). If the vertical OCT B-scan detected subretinal fluid (SRF) involving the central foveola with the IRF not involving the central foveola, the
eyes were classified into the one-side IRF group in the present study. Two retinal specialists (H.S. and H.I.) independently classified the eyes included in the two groups and were masked to the BCVA at the initial and 12 months visits and other patient information related to the eyes; a senior observer (M.Z.), who was also blinded to the patient data, made the final decision concerning the classification in case of disagreement.

Figure 1. A vertical optical coherence tomography (OCT) image of the right eye with intraretinal fluid (IRF) not involving the central foveola secondary to branch retinal vein occlusion of a 54-year-old woman. The OCT shows IRF (asterisks) not involving the central foveola (yellow arrow). The white arrow indicates the OCT scan direction. This eye was classified into the one-side IRF group.

Figure 2. A vertical optical coherence tomography (OCT) image of the right eye with intraretinal fluid (IRF) involving the central foveola secondary to branch retinal vein occlusion of an 85-year-old woman. The OCT image shows IRF (asterisks) involving the central foveola (yellow arrow) and subretinal fluid. The white arrow indicates the OCT scan direction. This eye was classified into the both-sides IRF group.
2.4. Assessment of the Foveal Ellipsoid Zone Band at 12 Months after the Initial Treatment

Based on the vertical OCT B-scan image through the fovea at 12 months after the initial treatment, one observer (H.S.) evaluated the foveal EZ band continuity (Figures 3 and 4) and was masked to the BCVA at the 12 months; a senior observer (M.Z.), who was also blinded to the patient data, made the final decision concerning the ambiguous cases.

Figure 3. A vertical optical coherence tomography (OCT) image of the left eye secondary to branch retinal vein occlusion of a 43-year-old man at initial visit and 12 months after the initial treatment. (A) Based on the initial vertical OCT image, this eye was classified into the one-side intraretinal fluid group. (B) The OCT image at the 12 months following the initial treatment shows the absence of disruption of foveal ellipsoid zone band (yellow arrow); the best-corrected visual acuity of the patient was 1.5. The white arrows indicate the OCT scan direction (A,B).
**Figure 4.** A vertical optical coherence tomography (OCT) image of the left eye secondary to branch retinal vein occlusion of an 87-year-old woman at initial visit and 12 months following the initial treatment. (A) Based on the initial vertical OCT image, this eye was classified into the both-sides intraretinal fluid group. (B) The OCT image at the 12 months following the initial treatment shows disruption of the foveal external limiting membrane and ellipsoid zone band (yellow arrow); the best-corrected visual acuity of the patient was 0.4. The white arrows indicate the OCT scan direction (A,B).

2.5. **Statistical Analysis**

A biostatistician (K.M.) performed the statistical analyses using SAS version 9.4 software (SAS Institute, Inc., Cary, NC, USA). Normality was evaluated using the Shapiro–Wilk test. The Wilcoxon signed-rank test was used for the paired analyses. The Mann–Whitney U test was used for the unpaired analyses. Differences in the categorical data between the two groups were analyzed using Fisher’s exact test. Multiple regression analysis was performed to identify explanatory variables with a statistically significant contribution to logMAR BCVA 12 months after the initial treatment. In this model, logMAR BCVA at 12 months was set as the objective variable. Groups (one-side or both-sides IRF), patient age, baseline
logMAR BCVA, baseline CST and presence of SRF were set as explanatory variables upon confirming the absence of multicollinearity among these explanatory variables. All the values are expressed as the mean ± standard deviation. Statistical significance was set at \( p < 0.05 \).

3. Results

3.1. Patient Characteristics

Fifty eyes from 50 patients met the study criteria for the analysis. A summary of the patient characteristics is presented in Table 1. The logMAR BCVA and CST at 12 months following the initial treatment showed significant improvement (\( p < 0.001 \) and \( p < 0.001 \), respectively) compared to the baseline values.

Table 1. A summary of the patient characteristics and optical coherence tomographic findings.

| Parameters                                      | Value     | \( p \)-Value |
|-------------------------------------------------|-----------|--------------|
| No. of eyes                                      | 50        |              |
| Baseline                                        |           |              |
| Age (years)                                     | 67.2 ± 12 |              |
| Sex (male/female)                               | 16/34     |              |
| Eye (right/left)                                | 22/28     |              |
| No. of cases of hypertension (%)                | 24 (48)   |              |
| No. of cases of diabetes mellitus (%)           | 9 (18)    |              |
| No. of cases of dyslipidemia (%)                | 10 (20)   |              |
| BRVO subtype (major/macular)                    | 42/8      |              |
| Perfusion status (ischemic/non-ischemic)        | 32/18     |              |
| Hemorrhage area (mm\(^2\))                      | 155.3 ± 92.7 |            |
| No. of cases of scatter laser photocoagulations (%) | 22 (44) |              |
| Duration before initial treatment (weeks)        | 5.4 ± 5.1 |              |
| Total no. of injections                         | 3.9 ± 1.6 |              |
| No. of eyes with one-side IRF/both-sides IRF    | 33/17     |              |
| LogMAR BCVA                                     | 0.29 ± 0.27 |            |
| Central subfield thickness (µm)                 | 512.2 ± 137 |          |
| Presence of subretinal fluid (%)                | 21 (42)   |              |
| 12 months following the initial treatment       |           |              |
| LogMAR BCVA                                     | 0.061 ± 0.2 | <0.001 *   |
| Central subfield thickness (µm)                 | 336.5 ± 112.2 | <0.001 *  |
| Presence of subretinal fluid (%)                | 1 (2)     |              |
| No. of eyes with foveal EZ band disruption (%)  | 9 (18)    |              |

\* Comparisons between the parameters at the baseline and 12 months were analyzed using the Wilcoxon signed-rank test. ¹ Two eyes were excluded due to missing data. Data are expressed as the mean ± standard deviation. BCVA, best-corrected visual acuity; BRVO, branch retinal vein occlusion; EZ, ellipsoid zone; IRF, intraretinal fluid; LogMAR, logarithm of the minimum angle of resolution; No., number.

3.2. Comparison of the two Groups According to Foveal Intraretinal Fluid Localization

A summary of the patient characteristics of the two groups is presented in Table 2. The logMAR BCVAs at baseline and 12 months were significantly better (\( p = 0.028 \) and \( p < 0.001 \), respectively) in the one-side IRF group compared to that in the both-sides IRF group. No eyes with decimal BCVA less than 0.5 were detected in the one-side IRF group at 12 months. The baseline CST was significantly lower (\( p < 0.001 \)) in the one-side IRF group than in the both-sides IRF group. However, the CST at 12 months did not differ significantly (\( p = 0.26 \)) between the two groups.
Table 2. A summary of the patient characteristics of the two groups.

| Parameters | One-Side IRF | Both-Sides IRF | p-Value |
|------------|-------------|---------------|---------|
| No. of eyes | 33          | 17            |         |
| Age (years) | 66.7 ± 11.3 | 68.1 ± 13.5 | 0.71    |
| BRVO subtype (major/macular) | 26/7 | 16/1 | 0.24    |
| Perfusion status (ischemic/non-ischemic) | 21/12 | 11/6 | 1       |
| Hemorrhage area (mm²) | 145.4 ± 94.0 | 159.4 ± 95.8 | 0.52 |
| Duration before initial treatment (weeks) | 5.1 ± 5.7 | 6.1 ± 3.7 | 0.15 |
| Total no. of injections | 3.8 ± 1.6 | 4.1 ± 1.5 | 0.4   |
| LogMAR BCVA | 0.21 ± 0.2 | 0.43 ± 0.4 | 0.028 |
| Central subfield thickness (µm) | 464.5 ± 125.9 | 604.7 ± 109.6 | <0.001 |
| Presence of subretinal fluid (%) | 9 (27.3) | 12 (70.6) | 0.006 |

12 months following the initial treatment

| Parameters | One-Side IRF | Both-Sides IRF | p-Value |
|------------|-------------|---------------|---------|
| LogMAR BCVA | −0.023 ± 0.1 | 0.22 ± 0.2 | <0.001 |
| Central subfield thickness (µm) | 321.5 ± 95.8 | 365.5 ± 137.4 | 0.26 |
| Presence of subretinal fluid (%) | 0 (0) | 1 (5.9) | 0.34 |
| No. of eyes with foveal EZ band disruption (%) |1(30,611),(998,636) | 8 (47.1) | <0.001 |
| No. of eyes with decimal BCVA of ≥0.5 (%) | 33 (100) | 12 (70.6) | 0.003 |

1Two eyes with one-side IRF were excluded due to missing data. Data are expressed as the mean ± standard deviation. BCVA, best-corrected visual acuity; BRVO, branch retinal vein occlusion; EZ, ellipsoid zone; IRF, intraretinal fluid; LogMAR, logarithm of the minimum angle of resolution; No., number.

3.3. Baseline Visual Prognostic Factors Associated with the Visual Acuity at 12 Months

In this study, we considered five explanatory variables that could contribute to the logMAR BCVA at 12 months following the initial treatment. The results of the multiple regression analyses are shown in Table 3. The multiple regression analyses demonstrated that baseline logMAR BCVA and the both-sides IRF group significantly correlated with the 12-months logMAR BCVA (p = 0.04, standardized coefficient = 0.28 and p = 0.001, standardized coefficient = 0.455). However, patient age, baseline CST and presence of SRF did not correlate with the 12-months logMAR BCVA (p = 0.19, p = 0.96 and p = 0.59).

Table 3. Baseline visual prognostic factors affecting the 12-months visual acuity in the multiple regression analysis.

| Explanatory Variables | Coefficient (95% CI) | p-Value | Standardized Coefficient |
|-----------------------|----------------------|---------|--------------------------|
| Both-sides IRF (compared to one-side IRF) | 0.19 (0.078 to 0.29) | 0.001 | 0.455 |
| LogMAR BCVA | 0.2 (0.01 to 0.4) | 0.04 | 0.28 |
| Age (years) | 0.003 (−0.001 to 0.007) | 0.19 | 0.166 |
| Central subfield thickness (µm) | 0.00001 (−0.0004 to 0.0004) | 0.96 | −0.008 |
| Subretinal fluid (presence) | 0.03 (−0.082 to 0.14) | 0.59 | 0.077 |

BCVA, best-corrected visual acuity; CI, confidence interval; IRF, intraretinal fluid; LogMAR, logarithm of the minimum angle of resolution.

4. Discussion

We investigated the visual prognostic factors in treatment-naive BRVO using OCT images in the current study. Although the CST at 12 months did not significantly differ between the two groups, the logMAR BCVA at 12 months following the initial treatment was significantly better in the one-side IRF group compared to that in the both-sides IRF group. We demonstrated that baseline logMAR BCVA and IRF localization were significantly associated with the 12-months logMAR BCVA. Moreover, no eyes with decimal BCVA less than 0.5 were detected in the one-side IRF group at 12 months. These findings suggest that IRF localization could be a novel biomarker for the visual prognosis of BRVO, along with baseline logMAR BCVA.

In this study, we selected a one + PRN regimen of intravitreal injections of aflibercept. This protocol was similar to that of previous studies [13,14]. LogMAR BCVA and CST improved significantly at 12 months compared to the baseline levels. The total number of
injections required for each patient was 3.9 ± 1.6 in this study. These results were similar to those of previous studies [13,14].

Previous studies have described baseline BCVA as a potential visual prognostic factors for BRVO [1–3]. Similarly, the baseline logMAR BCVA was significantly associated (p = 0.04, standardized coefficient = 0.28) with the logMAR BCVA at 12 months in this study. Considering our results and those of previous studies [1–3], patients with better baseline BCVA may have a good visual prognosis in BRVO. Meanwhile, the patient age was not associated with the logMAR BCVA at 12 months in this study. This could be attributed to the sample size [8].

Furthermore, we demonstrated that IRF localization was significantly associated (p = 0.001, standardized coefficient = 0.455) with logMAR BCVA at 12 months. This indicates that the visual prognosis of BRVO is worse in eyes with both-sides IRF than in eyes with one-side IRF. In this study, patients with ME secondary to BRVO were treated with a one + PRN regimen of intravitreal injections of aflibercept. Although the CST at 12 months and the total number of injections did not significantly differ between the two groups, the logMAR BCVA at 12 months was significantly worse in the both-sides IRF group compared to that in the one-side IRF group (Table 2). This could be attributed to the significantly greater disruption of the foveal EZ band in the both-sides IRF group compared to that in the one-side IRF group. The integrity of the photoreceptor layer in the fovea is presumably associated with visual acuity in resolved ME secondary to BRVO [15,16]. In this study, eyes with both-sides IRF had severe ME compared to eyes with one-side IRF. Moreover, SRF was significantly more frequently detected in eyes with both-sides IRF than in eyes with one-side IRF. A thicker CST, which demonstrates the severity of ME, could result in the disorganization of the photoreceptor structure and photoreceptor dysfunction [17,18]. In this study, the baseline CST was significantly higher in eyes with both-sides IRF than in eyes with one-side IRF. Thus, we consider eyes with both-sides IRF to more likely present with impaired integrity of the foveal photoreceptors, resulting in EZ disruption.

Previous studies have demonstrated a poor visual prognosis of eyes with SRF secondary to BRVO [19]. However, the effect of SRF on visual prognosis remains unclear [20,21]. In this study, eyes with both-sides IRF more frequently detected SRF compared to eyes with one-side IRF. However, the presence of SRF at the initial visit was not associated with the logMAR BCVA at 12 months. In addition, the effect of CST on the visual prognosis also remains unclear in BRVO [5–8]. In this study, baseline CST was significantly higher in the eyes with both-sides IRF than in the eyes with one-side IRF. However, baseline CST was also not associated with the logMAR BCVA at 12 months. Thus, we suggest that the IRF localization, but not baseline CST, is important for visual prognosis of BRVO. Since these results could be influenced by the sample size, individual factors and treatment strategies, prospective studies with uniform treatment strategies employing larger numbers of cases are warranted to elucidate the effect of these factors on the visual prognosis of BRVO.

No eyes with decimal BCVA less than 0.5 were detected in the one-side IRF group at 12 months (Table 2). This result suggests that eyes with one-side IRF have a better visual prognosis in BRVO. Considering the treatment strategy, initiating treatment before the IRF involves the central foveola on vertical OCT images could indicate a better visual prognosis in BRVO. IRF localization could aid in the treatment strategies for BRVO; however, further prospective studies are warranted to confirm the usefulness of this treatment strategy.

This study had several limitations. First, this was a retrospective study with an inherent sampling bias. Second, twenty-two eyes included in this study underwent scatter laser photocoagulation for the nonperfusion areas outside the vascular arcades, which may have resulted in a bias in the data. Third, the patients included in this study were followed up for only 12 months. Cases of EZ band recovery on the OCT images and associated BCVA improvement can be detected during follow-up periods over 12 months [22]. Although our study revealed that baseline IRF localization could contribute to the 12-months logMAR BCVA, longer follow-up studies are warranted to confirm our results.
Despite these limitations, our study has several strengths. We can easily classify the presence of one-side or both-sides IRF on the vertical OCT images in acute BRVO. Moreover, IRF localization may aid in the treatment of patients with BRVO.

5. Conclusions
Baseline IRF localization on vertical OCT images can aid in the prediction of the visual prognosis of BRVO. Eyes with one-side IRF may have a better visual prognosis in patients with BRVO.

Author Contributions: Conceptualization, H.S.; methodology, H.S. and M.Z.; software, K.M.; validation, H.S., M.Z. and Y.U.; data curation, H.S., R.M. and H.I.; writing—original draft preparation, H.S.; writing—review and editing, M.Z.; visualization, H.S.; supervision, H.S.; project administration, H.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Shinseikai Toyama Hospital (reference number: 220422-1).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The datasets used in this study are available from the corresponding author upon reasonable request.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Kondo, M.; Kondo, N.; Ito, Y.; Kachi, S.; Kikuchi, M.; Yasuma, T.R.; Ota, I.; Kensaku, M.; Terasaki, H. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: Results after 12 months and multiple regression analysis. *Retina* 2009, 29, 1242–1248. [CrossRef] [PubMed]
2. Jaisse, G.B.; Szurman, P.; Feltgen, N.; Spitzer, B.; Pielen, A.; Rehak, M.; Spital, G.; Heimann, H.; Meyer, C.H.; Retinal Vein Occlusion Study Group. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. *Graefes Arch. Clin. Exp. Ophthalmol.* 2011, 249, 183–192. [CrossRef] [PubMed]
3. Iida-Miwa, Y.; Muraoka, Y.; Iida, Y.; Ooto, S.; Murakami, T.; Suzuma, K.; Tsujikawa, A. Branch retinal vein occlusion: Treatment outcomes according to the retinal nonperfusion area, clinical subtype, and crossing pattern. *Sci. Rep.* 2019, 25, 6569. [CrossRef] [PubMed]
4. Scott, I.U.; Van Veldhuisen, P.C.; Oden, N.L.; Ip, M.S.; Blodi, B.A.; Hartnett, M.E.; Cohen, G. Standard Care versus Corticosteroid for Retinal Vein Occlusion Study Investigator Group. Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus Corticosteroid for Retinal Vein Occlusion Study report 10. *Ophthalmology* 2011, 118, 345–352.
5. Ota, M.; Tsujikawa, A.; Murakami, T.; Yamaike, N.; Sakamoto, A.; Kotera, Y.; Miyamoto, K.; Kita, M.; Yoshimura, N. Foveal photoreceptor layer in eyes with persistent cystoid macular edema associated with branch retinal vein occlusion. *Am. J. Ophthalmol.* 2008, 145, 273–280. [CrossRef]
6. Krieckbaum, K.; Michels, M.; Prager, F.; Georgopoulos, M.; Funk, M.; Geitzenuer, W.; Schmidt-Erfurth, U. Intravitreal avastin for macular oedema secondary to retinal vein occlusion: A prospective study. *Br. J. Ophthalmol.* 2008, 92, 518–522. [CrossRef]
7. Hoeh, A.E.; Ruppenstein, M.; Ach, T.; Dithmar, S. OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion. *Graefes Arch. Clin. Exp. Ophthalmol.* 2010, 248, 1567–1572. [CrossRef]
8. Kang, H.M.; Chung, E.J.; Kim, Y.M.; Koh, H.J. Spectral-domain optical coherence tomography (SD-OCT) patterns and response to intravitreal bevacizumab therapy in macular edema associated with branch retinal vein occlusion. *Graefes Arch. Clin. Exp. Ophthalmol.* 2013, 251, 501–508. [CrossRef]
9. Shiono, A.; Kogo, J.; Sasaki, H.; Yomoda, R.; Jujo, T.; Tokuda, N.; Kitaoka, Y.; Takagi, H. Optical coherence tomography findings as a predictor of clinical course in patients with branch retinal vein occlusion treated with ranibizumab. *PLoS ONE* 2018, 13, e0199552. [CrossRef]
10. Mimouni, M.; Segev, O.; Dori, D.; Geffen, N.; Flores, V.; Segal, O. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with macular edema secondary to vein occlusion. *Am. J. Ophthalmol.* 2017, 182, 160–167. [CrossRef]
11. The Branch Vein Occlusion Study Group. Argon laser photoagulation for macular edema in branch vein occlusion. *Am. J. Ophthalmol.* 1984, 98, 271–282. [CrossRef]
12. Heyreh, S.S.; Zimmerman, M.B. Fundus changes in branch retinal vein occlusion. *Retina* 2015, 35, 1016–1027. [CrossRef] [PubMed]
13. Miwa, Y.; Muraoka, Y.; Osaka, R.; Ooto, S.; Murakami, T.; Suzuma, K.; Takahashi, A.; Iida, Y.; Yoshimura, N.; Tsujikawa, A. Ranibizumab for macular edema after branch retinal vein occlusion: One initial injection versus three monthly injections. Retina 2017, 37, 702–709. [CrossRef]

14. Murata, T.; Kondo, M.; Inoue, M.; Nakao, S.; Osaka, R.; Shiragami, C.; Sogawa, K.; Mochizuki, A.; Shiraga, R.; Ohashi, Y.; et al. The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-naïve patients. Sci. Rep. 2021, 11, 551. [CrossRef] [PubMed]

15. Murakami, T.; Tsujikawa, A.; Ohta, M.; Miyamoto, K.; Kita, M.; Watanabe, D.; Takagi, H.; Yoshimura, N. Photoreceptor status after resolved macular edema in branch retinal vein occlusion treated with tissue plasminogen activator. Am. J. Ophthalmol. 2007, 143, 171–173. [CrossRef] [PubMed]

16. Ota, M.; Tsujikawa, A.; Murakami, T.; Kita, M.; Miyamoto, K.; Sakamoto, A.; Yamaike, N.; Yoshimura, N. Association between integrity of foveal photoreceptor layer and visual acuity in branch retinal vein occlusion. Br. J. Ophthalmol. 2007, 91, 1644–1649. [CrossRef] [PubMed]

17. Tso, M.O. Pathology of cystoid macular edema. Ophthalmology 1982, 89, 902–915. [CrossRef]

18. Wallow, I.H.; Danis, R.P.; Bindley, C.; Neider, M. Cystoid macular degeneration in experimental branch retinal vein occlusion. Ophthalmology 1988, 95, 1371–1379. [CrossRef]

19. Ohashi, H.; Oh, H.; Nishiwaki, H.; Nonaka, A.; Takagi, H. Delayed absorption of macular edema accompanying serous retinal detachment after grid laser treatment in patients with branch retinal vein occlusion. Ophthalmology 2004, 111, 2050–2056. [CrossRef]

20. Shroff, D.; Mehta, D.K.; Arora, R.; Narula, R.; Chauhan, D. Natural history of macular status in recent-onset branch retinal vein occlusion: An optical coherence tomography study. Int. Ophthalmol. 2008, 28, 261–268. [CrossRef]

21. Tsujikawa, A.; Sakamoto, A.; Ota, M.; Kotera, Y.; Oh, H.; Miyamoto, K.; Kita, M.; Yoshimura, N. Serous retinal detachment associated with retinal vein occlusion. Am. J. Ophthalmol. 2010, 149, 291–301.e5. [CrossRef] [PubMed]

22. Iijima, H. Mechanisms of vision loss in eyes with macular edema associated with retinal vein occlusion. Jpn. J. Ophthalmol. 2018, 62, 265–273. [CrossRef] [PubMed]